Table 1

Effects of plant sterol ester capsules on plasma lipid profiles and CRP (n = 16)1
Parameters
 Initial Baseline 2
 Day 7
 Day 21
 Δ PSE-Placebo
 Day 28
 Δ PSE-Placebo
Total Cholesterol (mg/dL)
 256.0 ± 24.3




Placebo phase
238.4 ± 18.8
 239.3 ± 28.3
241.6 ± 27.2
Treatment phase
239.9 ± 29.6
 237.4 ± 29.2
 -1.9 (-1%)
 230.4 ± 22.3
 -11.2 (-5%)
LDL (mg/dL)
 177.1 ± 22.8




Placebo phase
168.5 ± 22.9
 169.8 ± 25.6
169.4 ± 27.0
Treatment phase
170.8 ± 27.7
 157.8 ± 22.8 A, a
 -12 (-7%)
 163.3 ± 27.0A
 -6.1 (-4%)
HDL (mg/dL)
 57.8 ± 19.9




Placebo phase
50.4 ± 13.8
 49.1 ± 13.6
51.2 ± 15.4
Treatment phase
50.8 ± 15.5
 53.3 ± 16.3A, a
 4.2 (9%)
 53.5 ± 16.3a
 2.3 (4%)
Triglycerides
 125.9 ± 81.4




Placebo phase
116.6 ± 60.8
 122.7 ± 89.0
126.5 ± 74.6
Treatment phase
111.4 ± 69.8
 121.7 ± 71.4
 -1 (< -1%)
 115.7 ± 63.6
 -10.8 (-9%)
Total Cholesterol/HDL
 4.89 ± 1.64




Placebo phase
5.1 ± 1.4
 5.2 ± 1.6
5.1 ± 1.6
Treatment phase
5.1 ± 1.5
 4.8 ± 1.6A, a
 -0.4 (-8%)
 4.7 ± 1.4A, a
 -0.4 (-8%)
LDL/HDL
 3.44 ± 1.28




Placebo phase
3.6 ± 1.3
 3.6 ± 1.2
3.7 ± 1.2
Treatment phase
3.7 ± 1.2
 3.4 ± 1.2 A, a
 -0.2 (-6%)
 3.3 ± 1.2A, a
 -0.4 (-10%)
CRP (mg/dL)
 0.8 ± 0.5




Placebo phase
0.7 ± 0.4
 0.7 ± 0.4
0.7 ± 0.5
Treatment phase
0.8 ± 0.6
 0.8 ± 0.5
 0.07 (5%)
 0.7 ± 0.3
 0

1 Values are means ± SD.

2 Initial baseline measurement was done 6 week before the placebo phase. Therefore, the data was not included in any analysis, but are provided as reference information

A Significantly different from placebo, p < 0.05 (paired t-test)

a Significantly different within phase, p < 0.05 (1-way repeated measure ANOVA)

Acuff et al. Lipids in Health and Disease 2007 6:11   doi:10.1186/1476-511X-6-11